Routine Neutral

2026-05-21 17:55

Syngene International Limited has sent a reminder letter to shareholders for claiming unclaimed dividends from FY 2018-19 onwards and updating KYC information. Shareholders are requested to claim their dividends and update KYC by August 21, 2026, to avoid the transfer of corresponding equity shares to the Investor Education and Protection Fund (IEPF) Authority, as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and IEPF Rules.

Governance Positive

2026-05-20 22:01

Syngene International Limited is conducting a postal ballot to seek shareholder approval for the change in role of Ms. Kiran Mazumdar-Shaw from Non-Executive Chairperson to Executive Chairperson (a Key Managerial Personnel) for a period of 5 years, effective April 1, 2026. Her annual managerial remuneration will not exceed ₹4.00 Crores. The e-voting period is from May 21, 2026, to June 19, 2026, with results expected by June 23, 2026.

Business Update Neutral

2026-05-18 22:44

Syngene International Limited's Board approved the voluntary liquidation of Syngene Manufacturing Solutions Limited (SMSL), a wholly-owned, non-material and solvent subsidiary, on May 18, 2026. SMSL has no business operations and its liquidation will not materially impact the Company's consolidated financials. For FY26, SMSL's turnover was Nil and net worth was ₹93.98 lakhs, representing 0.02% of the parent's net worth.

Routine Neutral

2026-05-04 21:37

New Filing detected. See link for details.

Routine Neutral

2026-04-30 17:22

New Filing detected. See link for details.

Financials Negative

2026-04-29 21:37

Consolidated Revenue ₹10,365 million vs ₹10,180 million (▲1.8% YoY), EBITDA ₹2,974 million vs ₹3,436 million (▼13.4% YoY), PAT ₹1,479 million vs ₹1,833 million (▼19.3% YoY) for the quarter ended March 31, 2026. EBITDA Margin was 28.7% vs 33.8% (▼510 bps). The Board also recommended a final dividend of Re.1.25/- per equity share for the financial year 2025-26 and approved the appointment of M/s S. R. Batliboi & Associates LLP as statutory auditors for five years.

Governance Negative

2026-04-29 19:09

CRITICAL RED FLAG DETECTED

Syngene International Limited announced a change in Key Managerial Personnel. Mr. Peter Bains will step down as Managing Director & CEO effective June 30, 2026. Mr. Siddharth Mittal has been appointed as the new Managing Director & CEO, effective July 01, 2026.

Ownership Neutral

2026-04-29 19:07

The Board of Directors of Syngene International Limited, at its meeting on April 29, 2026, approved the allotment of 7,29,727 equity shares to the Syngene Employee Welfare Trust under the Syngene Long Term Incentive Performance Share Plan 2023. Consequent to this allotment, the paid-up share capital of the Company has increased from Rs. 402,93,94,200 (40,29,39,420 equity shares) to Rs. 403,66,91,470 (40,36,69,147 equity shares).

Financials Negative

2026-04-29 18:59

Syngene International Limited reported Q4 FY26 consolidated results with revenue at ₹10,365 million (▲1.8% YoY), EBITDA at ₹2,974 million (▼13.4% YoY), and PAT at ₹1,479 million (▼19.3% YoY). EBITDA margin contracted by 506 bps to 28.7%. The Board recommended a final dividend of Re.1.25/- per equity share and approved the appointment of S. R. Batliboi & Associates LLP as statutory auditors.

Governance Neutral

2026-04-29 18:55

Syngene International Limited announced the appointment of Mr. Vijaya Chandru and Mr. Arun Chandavarkar as Additional Independent Non-Executive Directors, effective from the 33rd Annual General Meeting until 2029. The company also reappointed Ms. Vinita Bali as an Additional Non-Executive Director for one year from July 22, 2026, to July 21, 2027. All appointments are subject to shareholder approval.

Financials Negative

2026-04-29 18:52

For Q4 FY26, Syngene International Limited reported Revenue from Operations of ₹1,037 Cr vs ₹1,018 Cr (▲2% YoY), Operating EBITDA of ₹303 Cr vs ₹344 Cr (▼12% YoY), and PAT (before exceptional items) of ₹153 Cr vs ₹183 Cr (▼16% YoY). Operating EBITDA Margin was 29% vs 34% (▼500bps). The company also announced a final dividend of Rs. 1.25 per share.

Financials Negative

2026-04-29 18:46

Consolidated Revenue ₹1,036.5Cr vs ₹1,018.0Cr (▲1.8% YoY), EBITDA ₹297.4Cr vs ₹343.6Cr (▼13.4% YoY), PAT ₹147.9Cr vs ₹183.3Cr (▼19.3% YoY). EBITDA Margin 28.7% vs 33.8% (▼510bps). The company also recommended a final dividend of Re.1.25/- per Equity Share for FY25-26 and appointed S. R. Batliboi & Associates LLP as statutory auditors for 5 years.

Financials Negative

2026-04-29 18:37

Syngene International Limited reported Consolidated Revenue of ₹10,365 Mn vs ₹10,180 Mn (▲1.8% YoY), EBITDA of ₹3,256 Mn vs ₹3,625 Mn (▼10.2% YoY), and PAT of ₹1,479 Mn vs ₹1,833 Mn (▼19.3% YoY) for the quarter ended March 31, 2026. EBITDA Margin contracted from 35.6% to 31.4% (▼420bps). The Board also recommended a final dividend of Re 1.25 per equity share for FY26.

Financials Neutral

2026-04-22 17:53

Syngene International Limited announced a conference call for Analysts and Investors on Thursday, April 30, 2026, at 2:00 PM IST to discuss its Q4 and full year FY2026 financial results.

Routine Neutral

2026-04-08 18:59

New Filing detected. See link for details.

Business Update Positive

2026-03-29 13:52

Syngene provided an update on tax litigations. The High Court allowed its writ petition, and NFAC partially allowed an appeal. This led to a refund of Rs. 43.16 Cr (including interest) for AY 2016-17 and a decrease in contingent liability, with no material financial impact expected.

Governance Neutral

2026-03-27 18:56

CRITICAL RED FLAG DETECTED

Syngene announced leadership changes: Mr. Peter Bains resigns as MD & CEO, effective June 30, 2026. Mr. Siddharth Mittal is appointed as the new MD & CEO, effective July 01, 2026. Ms. Kiran Mazumdar Shaw's role changes to Executive Chairperson, effective April 01, 2026.

Ownership Neutral

2026-03-27 16:20

Syngene International Limited announced the closure of the trading window from April 1, 2026, until 48 hours after the declaration of audited financial results for the quarter and year ending March 31, 2026, in compliance with SEBI insider trading regulations.

Business Update Neutral

2026-03-16 17:16

Syngene International Limited will hold a virtual one-on-one meeting with OrbiMed Advisors LLC on March 19, 2026, at 11:00 AM IST. The company confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed during the meeting.

Business Update Positive

2026-03-14 18:54

Syngene International Limited announced an update on tax litigation for AY 2018-19. The National Faceless Assessment Centre dropped penalty proceedings on March 13, 2026, and allowed relief for an earlier disallowance of Rs.2.78 crore, resulting in no material financial impact.

Business Update Neutral

2026-03-13 15:39

Syngene International Limited intimated a virtual one-to-one meeting with Alquity Investment Management scheduled for March 18, 2026, at 4:00 PM IST. The company confirmed no Unpublished Price Sensitive Information will be disclosed during the meeting.

Business Update Neutral

2026-03-11 18:43

Syngene International Limited announced an analyst/institutional investor meeting with Multi-Act Equity Consultancy Pvt. Ltd on March 16, 2026. The virtual one-to-one meeting will not involve the disclosure of Unpublished Price Sensitive Information (UPSI).

Governance Negative

2026-03-06 16:07

CRITICAL RED FLAG DETECTED

Syngene announced Senior Management Personnel changes. Ms. Caroline Hempstead (CCO), Mr. Andrew Webster (CHRO), and Dr. Kenneth Barr (Head of SynVent) will leave by April 30, 2026. Mr. Abhijit Zutshi is the new CCO and Ms. Maninder Singh Puri the new CHRO, effective May 1, 2026.

Business Update Neutral

2026-02-20 16:23

Syngene International Limited intimated a one-to-one physical meeting with Tata MF on February 25, 2026, at 3:15 PM in Bengaluru. The company confirmed that no Unpublished Price Sensitive Information would be disclosed during the analyst/investor meeting.

Business Update Positive

2026-02-18 16:52

Syngene received partial relief from the National Faceless Appeal Centre (NFAC) in tax appeals for Assessment Years 2015-16, 2018-19, and 2021-22. This is expected to reduce contingent liability and make the company eligible for a refund, with no material financial impact or penalties imposed.

Business Update Neutral

2026-02-17 17:49

Syngene International Limited announced a virtual one-to-one meeting with Renaissance Investment Managers scheduled for February 23, 2026, at 4:45 PM IST. The company confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed during the meeting.

Business Update Positive

2026-02-14 21:17

Syngene International Limited received a tax refund cheque of Rs. 25.47 Cr on February 13, 2026. This follows the Hon'ble High Court allowing the company's writ petition regarding tax assessments for AY 2010-11, 2011-12, and 2012-13, with the refund for AY 2014-15.

Business Update Positive

2026-02-14 21:15

Syngene International Limited announced an update on tax litigations for AY 2013-14, 2014-15, and 2017-18. The National Faceless Appeal Centre (NFAC) partially allowed relief to the company, which expects a reduction in contingent liability and eligibility for a refund. No penalties were imposed.

Business Update Positive

2026-02-14 21:12

Syngene International Limited provided an update on tax litigation where the National Faceless Appeal Centre (NFAC) directed the Assessing Officer to verify details and allow relief to the company regarding a disallowance from Assessment Year 2012-13. The company expects no material financial impact.

Business Update Neutral

2026-02-06 18:52

Syngene International Limited intimated scheduled meetings with analysts/institutional investors on February 10 and 11, 2026, in Mumbai, including the Advantage India - Axis Capital's Flagship India Conference. No Unpublished Price Sensitive Information will be disclosed.

SYNGENE

Syngene International Limited

Filing History

Unlock Full History